Orphan drug designation plea for Delta-9-Tetrahydrocannibinol and Cannabidiol
PhytoPain Pharma Inc., a part of GrowPros Cannabis Ventures Inc., declares the submission of applications.
Release Date: 10-Oct-2016
PhytoPain Pharma Inc., a part of GrowPros Cannabis Ventures Inc., declares the submission of applications for orphan drug designation status for Delta-9-Tetrahydrocannibinol and Cannabidiol for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS1) and Central PostStroke Pain (CPSP). Also, it will help in treatment of neuropathic pain associated with cancer, HIV, CPSP, and CRPS1. The aim is to commercialize the drug for the management of uncontrolled pain related to life threatening diseases.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.